Overview

NOX-100 for Preventing Hypotension During Hemodialysis

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability and efficacy profile of NOX-100 to reduce intradialytic hypotension (IDH) in patients undergoing chronic hemodialysis (HD).
Phase:
Phase 2
Details
Lead Sponsor:
Medinox, Inc.
Collaborator:
Orient Europharma Co., Ltd.
Treatments:
Nitric Oxide